Fulcrum Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -300 | -369 | ||
EBITDA | -19,249 | -16,952 | -20,050 | -16,199 |
EBIT | -19,595 | -17,296 | -20,403 | -16,568 |
Net Income | -19,595 | -17,296 | -17,655 | -16,568 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -14,280 | -13,885 | -15,257 | -16,992 |
Cash | 47,078 | 42,588 | 42,178 | 58,212 |
Basic Shares | 62,597 | 62,544 | 62,479 | 53,954 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $80,000 | $2,805 | $6,342 | $19,163 |
Gross Profit | 16,614 | 2,805 | -70,440 | 19,163 |
EBITDA | -18,241 | -108,492 | -109,720 | -78,539 |
EBIT | -19,834 | -110,664 | -112,134 | -81,054 |
Net Income | -9,725 | -97,335 | -109,871 | -78,332 |
Net Change In Cash | 80,000 | 2,805 | 6,342 | 19,163 |
Cost of Revenue | -314 | -21,640 | ||
Free Cash Flow | -2,496 | -91,473 | -99,013 | -80,191 |
Cash | 58,212 | 25,563 | 35,098 | 35,412 |
Basic Shares | 61,984 | 61,310 | 44,991 | 35,361 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.31 |
2025-06-30 | -$0.28 |
2025-03-31 | -$0.28 |
